Dr. Grivas (US) elaborates on his study “Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC)” which he presented at ASCO GU22.
Dr. Grivas (US) elaborates on his study “Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC)” which he presented at ASCO GU22.